Kayentis
Health Care · Clinical Trial Software
Has an LEI
100–199EmployeesFrench register · Dec 2024 ↗
Lately:6 news stories in 90 daysFollow changes →
Facts
as of Nov 20, 2026With a 95.9% recommendation rate in 2026, Kayentis is a trusted partner for biotech, emerging biopharma, and global pharmaceutical companies. Since 2005, Kayentis has supported pharma, biotechs, and CROs by capturing meaningful patient input.
- Legal name
- KAYENTIS SASactive
- Headquarters
- Meylan, France
- Founded
- 2003
- Employees
- 100–199French register · Dec 2024
- Revenue
- $23.2M2024 · French register (451664809)
- Register numbers
- SIREN 451664809
- Official records
- LEI 969500LK8GG5LPS1UR35
- Website
- kayentis.com
These are the key facts about Kayentis on Alion as of Nov 20, 2026. Kayentis is headquartered in Meylan, France. It was founded in 2003. It has raised $11.5M in 2 funding rounds. The latest round is Venture - Series Unknown of $7.6M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
KAYENTIS SAS · annuaire-entreprises.data.gouv.fr ↗
Yes
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Meylan France | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$23.2MRevenue2024
$11.5MTotal raised
Venture - Series UnknownLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
$7.6M
$3.9M
Sources: funding announcements, grant and company registers
Money
Kayentis has $11.5M paid in by investors, lenders and donors.
$11.5MPaid in
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
$7.6MPaid
$3.9MPaid
Taxes
No public tax figures for this company or its entities.
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Milestones
Oct 4
Raised a round Venture round $7.6M · pharmaphorum
Jun 24
Apr 15
Jan 15, 2023
Oct 18, 2016
Raised a round Venture round $3.9M
2003
Founded
Each milestone is dated by its source: registers, filings, the press
Newsroom
Oct 202026
Blog
Despite recent estimates showing a 7.1% enrollment rate in cancer treatment trials, surpassing historical figures of less than 5%, the challenges of recruiting and retaining pati…
Oct 162026
Blog
A Phase 1 oncology study went from kick-off to go-live in just 5 weeks, offering valuable lessons for accelerating study start-up. How Kayentis Delivered eCOA Go-Live in Just 5 W…
Oct 92026
Blog
A PHASE 1 ONCOLOGY STUDY IN ADULTS WITH METASTATIC BONE PAINKayentis delivered the electronic solution for daily capture of:an NRS-based pain instrument supporting the primary ef…
Oct 92026
Blog
Home Go back White Paper CNS Turning endpoint noise into reliable CNS trial data Most CNS trials don't fail because the therapy doesn't work. They fail because assessment variabi…
Oct 42026
News · pharmaphorum
French tech company Kayentis has raised €7 million in private funding that will be invested in its digital platform for clinical trials
Oct 22026
Blog
Meet our colleague Anna Dudalyan at CTAD. Schedule a meeting L'article CTAD Clinical Trial on Alzheimer's Disesases est apparu en premier sur Kayentis.
Sources: the outlets named on each headline, each story once
